Trial Profile
Prospective, Randomised, Controlled Phase 2 Study Investigating the Haemostatic Efficacy and Safety of Fibrinogen Concentrate (Octafibrin) and Cryoprecipitate as Fibrinogen Supplementation Sources in Patients Undergoing Cytoreductive Surgery for Pseudomyxoma Peritonei
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2020
Price :
$35
*
At a glance
- Drugs Fibrinogen (Primary) ; Fibrinogen
- Indications Surgical blood loss
- Focus Registrational; Therapeutic Use
- Acronyms FORMA-05
- Sponsors Octapharma
- 05 Oct 2020 Results (n=45) of sub-analysis assessing intra-operative and postoperative coagulation profiles presented at the ANESTHESIOLOGY 2020 Annual Meeting of the American Society of Anesthesiologists
- 05 Nov 2019 According to an Octapharma media release, the human fibrinogen concentrate fibryga has received approval for use in treatment of acquired fibrinogen deficiency (AFD) in 15 European countries. The approval extends the market authorisation for fibryga, which is already approved for use in patients with congenital fibrinogen deficiency.The approval of fibryga for use in AFD is based on results of this clinical (FORMA-05) study.
- 05 Nov 2019 According to Octapharma media release, results from this trial were discussed at American Society of Anesthesiologists Annual Meeting